Skip to main content
European Commission logo
Deutsch Deutsch
CORDIS - Forschungsergebnisse der EU
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Inhalt archiviert am 2024-06-18

Biofilm Alliance

Ziel

Infections by biofilm-forming microorganisms on indwelling medical devices such as catheters, prosthetic joints and internal fracture fixation devices pose a serious health threat. Overall, approximately 3% of all patients receiving such devices develop biofilm infections, with costs adding up to billions of Euro’s.
Current strategies to combat biofilms are based on conventional antibiotics. They often fail because 1) biofilms are difficult to penetrate, 2) micro-organisms in biofilms are resistant to most conventional antibiotics, 3) antibiotics cause release of pro-inflammatory microbial compounds, and 4) the locally available concentrations are too low.
The aim of BALI is to disrupt biofilm formation by a unique combination of Synthetic Antimicrobial Antibiofilm Peptides (SAAPs) with biofilm dispersing, microbicidal, and immune-orchestrating activity, incorporated in novel controlled release drug delivery formulations (PolyPid), for both prevention and treatment of biofilm infections. The recently developed SAAP OP-145, already tested in humans, will be the first candidate.
PolyPid, a unique polymer-lipid-based drug delivery platform will be tailored for coatings allowing prolonged and pre-determined release rates of SAAPs, to ensure the required local concentrations over a desired period. The coatings will be optimized in vitro and subsequently in mice and rabbit studies to prevent and treat biofilm infection. Finally a phase 1 study in patients with bone fracture fixation devices will be performed.
The novel SAAP-delivering PolyPid formulations can control biofilms and allows for treatment and management of infections, reducing infection rates of implanted medical devices. Patients relying on safe and effective medical devices thus will benefit strongly by reduction of infection frequencies. Besides improved health of EU citizens, the associated cost savings for hospitals and the economic benefits for the SMEs contribute to realization of EC policies

Aufforderung zur Vorschlagseinreichung

FP7-HEALTH-2011-two-stage
Andere Projekte für diesen Aufruf anzeigen

Koordinator

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
EU-Beitrag
€ 618 845,96
Adresse
MEIBERGDREEF 15
1105AZ Amsterdam
Niederlande

Auf der Karte ansehen

Region
West-Nederland Noord-Holland Groot-Amsterdam
Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Frank J.M. Groen
Links
Gesamtkosten
Keine Daten

Beteiligte (8)